Chlorotrianisene

Overview

A powerful synthetic, non-steroidal estrogen. [PubChem]

Indication

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Single-arm Clinical Trial of TACE in Combination With Acoradine as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence	2024/10/16	NCT06644937	Phase 2	Not yet recruiting	Zhujiang Hospital
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study	2023/09/06	NCT06024252	N/A	Not yet recruiting	Zhongda Hospital
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma	2023/08/01	NCT05970666	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma	2022/09/26	NCT05555316	Phase 2	Recruiting	Sun Yat-sen University
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)	2022/04/22	NCT05340231	Phase 2	Not yet recruiting	Gang Wu
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection	2021/07/29	NCT04981665	Phase 2	Recruiting	Zhejiang University
Perioperative Therapy for Hepatocellular Carcinoma	2020/12/04	NCT04653389	Phase 2	Terminated	Zhejiang University
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC	2020/10/23	NCT04599790	Phase 2	Completed	Second Affiliated Hospital of Guangzhou Medical University
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC	2020/10/23	NCT04599777	Phase 2	Completed	Second Affiliated Hospital of Guangzhou Medical University
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC	2020/10/19	NCT04592029	Phase 1	UNKNOWN	Second Affiliated Hospital of Guangzhou Medical University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Type 2 Diabetes Significantly Increases Risk of MASH Progression to Cirrhosis, New Target RWE Study Reveals

4 months ago

New research from Target RWE presented at EASL 2025 demonstrates that individuals with Type 2 diabetes have significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group.

Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies

7 months ago

Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.

TACE Plus Camrelizumab and Rivoceranib Improves PFS in Unresectable HCC

8 months ago

The CARES-005 study demonstrated that adding camrelizumab and rivoceranib to TACE significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC).

Lenvatinib and Pembrolizumab Plus TACE Improves Progression-Free Survival in Unresectable HCC

9 months ago

The LEAP-012 phase III trial demonstrated that adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with unresectable nonmetastatic hepatocellular carcinoma (HCC).

Comparative Effectiveness of Locoregional Therapies for Hepatocellular Carcinoma Assessed